Cancer Drugs Fund requires further reform
Reliance on “real world” observational data undermines evidence base for clinical practice.
Autors principals: | Grieve, R, Abrams, K, Claxton, K, Goldacre, B, James, N, Nicholl, J, Parmar, M, Parker, C, Sekhon, J, Smeeth, L, Spiegelhalter, D, Sculpher, M |
---|---|
Format: | Journal article |
Idioma: | English |
Publicat: |
BMJ Publishing Group
2016
|
Ítems similars
-
Huang Shu Yin funded for further study
per: Kwong Wah, Yit Poh
Publicat: (2017) -
Huang Shu Yin Funded For Further Study
per: Kwong Wah, Yit Poh
Publicat: (2017) -
MRE in NAFLD: promising but further validation is required
per: Ryan, J, et al.
Publicat: (2018) -
Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals
per: Morrell, L, et al.
Publicat: (2018) -
Bladder cancer: issues requiring further research
per: I. A. Rozhkov, et al.
Publicat: (2024-09-01)